Document is current
Any future updates will be listed below
-
Authors
,
López, Saioa
Lim, Emilia L.
Horswell, Stuart
Haase, Kerstin https://orcid.org/0000-0002-0944-5618
Huebner, Ariana
Dietzen, Michelle
Mourikis, Thanos P.
Watkins, Thomas B. K.
Rowan, Andrew
Dewhurst, Sally M.
Birkbak, Nicolai J. https://orcid.org/0000-0003-1613-9587
Wilson, Gareth A.
Van Loo, Peter https://orcid.org/0000-0003-0292-1949
Jamal-Hanjani, Mariam
Swanton, Charles https://orcid.org/0000-0002-4299-3018
McGranahan, Nicholas https://orcid.org/0000-0001-9537-4045
-
Funding
Funding for this research was provided by:
Wellcome Trust (211179/Z/18/Z)
Wellcome Trust (FC001169, FC001202)
CRUK Lung Cancer Centre of Excellence, Rosetrees Trust, and the NIHR BRC at University College London Hospitals
Cancer Research UK (FC001169, FC001202)
Novo Nordisk Fonden (ID16584)
EIF | Stand Up To Cancer (SU2C-AACR-DT23-17)
- License Information
-
More Information
Article History
Received: 21 December 2018
Accepted: 28 January 2020
First Online: 5 March 2020
Competing interests
: C.S. receives grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana and Boehringer-Ingelheim. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience and GRAIL, and has stock options in and is co-founder of Achilles Therapeutics. N.M. has received consultancy fees from Achilles Therapeutics.
